The team of Immunic very much appreciates your interest in participating in our Phase 2 program. We are planning to conduct a full Phase 2 program for IMU-838 in the indication IBD, including separate Phase 2 trials in ulcerative colitis (CALDOSE-1) and Crohn’s disease (CALDOSE-2).

This web site is intended to give you as medical professional more information about the drug and the Phase 2 program so that you can judge your interest in participating in these trials.

The main objective of this Phase 2 program is to establish the optimal dose of IMU-838 for treatment of IBD patients to evaluate time Course and efficiency of IMU-838 activity and to investigate safety and tolerability of IMU-838 in IBD patients.


Immunic offers more detailed study information to interested medical professionals in a password-secured area. Please request your access key here: